Results 241 to 250 of about 100,944 (279)
Favorable coronary outcomes following IL-6 blockade with tocilizumab in IVIG-resistant kawasaki disease: a case series. [PDF]
Front ImmunolZheng J +5 more
europepmc +1 more source
Hemophagocytic Lymphohistiocytosis as First Manifestation of Dual B-Cell Neoplasms: A Case Report of Co-Existing Multiple Myeloma and B-Cell Lymphoma. [PDF]
EJHaemRomagnoli C +6 more
europepmc +1 more source
Basophil Activation Test for the In Vitro Diagnosis of Tocilizumab Hypersensitivity
Clinical &Experimental Allergy, Volume 56, Issue 5, Page 559-561, May 2026.
Ana Koren +3 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tocilizumab in transplantation
European Journal of Clinical Pharmacology, 2020Tocilizumab, a monoclonal antibody directed against the IL-6 receptor, might block detrimental effects of IL-6 on transplantation. IL-6 plays a considerable role in cytokine storm after stem cell transplantation as well as graft versus host disease, and it has also been shown to be involved in solid organ allograft rejection; therefore, tocilizumab is ...
Banafsheh, Mosharmovahed +4 more
openaire +2 more sources
CT-P47/Tocilizumab-anoh: A Tocilizumab Biosimilar
Clinical Drug InvestigationCT-P47/tocilizumab-anoh (AVTOZMA®) is a biosimilar of reference tocilizumab, an IL-6R inhibitor. CT-P47 is approved for treating rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, Coronavirus disease 2019 and cytokine release syndrome in the USA and the EU. CT-P47 has similar
openaire +2 more sources
Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +1 more source